 SAN DIEGO, Aug. 09, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento, a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrentos proprietary mRNA vaccine development program for COVID-19. 